William Blair Investment Management LLC Purchases New Position in Repligen Corporation $RGEN

William Blair Investment Management LLC acquired a new stake in Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 788,571 shares of the biotechnology company’s stock, valued at approximately $107,593,000.

Several other institutional investors have also added to or reduced their stakes in RGEN. AQR Capital Management LLC bought a new stake in shares of Repligen in the 1st quarter worth $262,000. Jones Financial Companies Lllp raised its stake in shares of Repligen by 3,850.6% in the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock worth $814,000 after purchasing an additional 6,238 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Repligen by 16.8% during the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after purchasing an additional 20,375 shares in the last quarter. Bank of Nova Scotia lifted its holdings in shares of Repligen by 88.0% during the second quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock valued at $3,951,000 after purchasing an additional 14,860 shares in the last quarter. Finally, Daiwa Securities Group Inc. boosted its position in shares of Repligen by 29.7% during the second quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock valued at $3,880,000 after buying an additional 7,148 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on RGEN. Zacks Research upgraded shares of Repligen from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 13th. HSBC dropped their target price on shares of Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Wolfe Research assumed coverage on Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price on the stock. Finally, Wells Fargo & Company boosted their price target on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $166.43.

Insider Activity at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.60% of the company’s stock.

Repligen Stock Performance

RGEN opened at $181.13 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The stock has a market capitalization of $10.22 billion, a price-to-earnings ratio of 248.12, a PEG ratio of 3.29 and a beta of 1.03. The company has a fifty day moving average of $147.16 and a 200 day moving average of $131.88. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $188.73.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business’s revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.26 EPS. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, sell-side analysts forecast that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.